drugset / Trial / NCT00447005

Study Of AG-013736 (Axitinib) In Patients With Advanced Solid Tumors

NCT00447005

Phase 1 Completed 12 enrolled Pfizer
Non-randomizedSingle-groupOpen-labelTreatment

Summary

To evaluate the clinically recommended dose of AG-013736 (Axitinib) in Japanese patients by reviewing the safety of AG-013736 (Axitinib) following single and multiple dosing.

Timeline

Start
2007-02
Primary completion
2009-08
Completion
2009-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Axitinib Small molecule 5 mg Oral

Indications